Bio-Techne Corp (TECH) stock analysis
Bio-Techne Corp (TECH) clears 1 of this site's 8 mechanical value filters, 3 of 8 Buffett-style checks and 1 of 5 Lynch-style checks. At $72.62 it trades 153.4% above this site's neutral DCF value (a margin of safety of -153.4%). Its earnings quality rates Strong and it returns +0.4% to shareholders net of dilution. Figures are as of October 23, 2026, from SEC filings and market data refreshed weekly; this is educational analysis, not investment advice.
Data as of October 23, 2026. Refreshed weekly from SEC filings and market data.
What does Bio-Techne do?
Bio-Techne makes the reagents, proteins and instruments that researchers use in labs, and diagnostics products for hospitals.
Brands and businesses it owns
- R&D Systems
- Novus
- Lunaphore
What stands out about Bio-Techne?
- The share price implies 32.2% yearly growth. At $72.62, TECH's free cash flow of $1.68 per share would have to grow 32.2% a year, fading to 2.5% by year 10, for this site's DCF (10% discount rate) to match the price. This site's baseline starts at 8%, so the price asks for more growth than the baseline. Change the assumptions.
- Misses 4 of the 8 value filters. It fails Market Cap > $25B ($11.4B), Trailing P/E < 25 (62.64) and PEG Ratio < 1.5 (9.81) and 1 more; the other 1 pass and 3 were not evaluated. See every filter.
- Close to its 52-week high. At $72.62, TECH is within 0.0% of its high of $72.64, 67.7% above its low of $43.30. See the range.
- Strongest against peers: debt / equity. At 0.09 (peer median 0.54) it ranks 2nd of 11 among life sciences tools & services stocks this site tracks. See the ranking.
- Weakest against peers: revenue growth. At −0.4% (peer median 6.9%) it ranks 10th of 11 among life sciences tools & services stocks this site tracks. See the ranking.
How has Bio-Techne's share price moved?
The interactive price chart needs JavaScript.
Is Bio-Techne undervalued? The value diligence check
Every value-investing signal this site computes for this stock, gathered in one place: the same real numbers from the tools below, not a new score.
- Margin of safety (DCF) -153.4%
- P/E vs. its own history 62.6x · near the cheap end Real range: 46.4x–112.6x over 5 years (net income per diluted share from each fiscal year's 10-K, paired with the real closing price at that fiscal year-end).
- Wall St. analyst rating Hold · 3.45/5 20 analysts this month: 3 strong buy, 3 buy, 14 hold, 0 sell, 0 strong sell (Finnhub).
- Earnings quality (is the profit real?) Strong · all 5 checks clean Beneish M-score −2.54 · accruals −4.3% of assets · 208% of profit arrived as cash · stock comp 3.4% of revenue · share count −1.2% a year. From the latest 10-K (year to Jun 2026) - see the Earnings Quality Screener for how each check is scored.
- Shareholder yield (cash back to owners) +0.4% net Latest fiscal year (2026): dividends 0.4% + buybacks 0.4% − stock comp 0.4%, as a share of today's market cap. Over 14 years its split-adjusted share count rose 6%. See Shareholder Yield Leaders.
- Capital needed to grow (See's test) $10.18 per $1 of new profit · Capital-hungry · but only 10% return on capital Operating profit $135M → $187M, capital needed $1.4B → $1.9B, 2017–2026 (3-year averages); return on capital now 10% before tax. Buffett's See's Candies needed $0.42 per $1 of new profit, FlightSafety $3.20, a typical grower about $5. See Capital-Light Compounders.
- PEG (growth at a reasonable price) 9.81 · Well above fair P/E 62.6× ÷ 6.4% a year of growth behind it. 429th lowest of 447 stocks with a usable PEG. Lynch's fair value is a PEG of 1; a very high PEG usually means almost no growth, a very low one a profit spike. See PEG Ratio Ranking.
- Compounder lenses (4) 2 of 4 · misses capital-light, price Capital-light growth: not cleared (profit grew 1.4×, under 2×); Profit is real: cleared; Cash to owners: cleared; Fair price (PEG): not cleared (PEG 9.81, over 1.5). See Compounders at a Fair Price, which also lets you move the PEG bar.
- Value trap check Clear
- Munger's Inversion Check 3 flags
- Standing vs. sector peers 2 of 7 measures above the median Compared with the 10 other life sciences tools & services stocks this site tracks: 1 in the top third, 3 in the bottom third.
- Dividend payout sustainability 0/6 · clean
How does Bio-Techne compare with its peers?
2 of 7 measures sit above the median of the 10 other life sciences tools & services stocks tracked here, 1 in the top third and 3 in the bottom third.
- P/E ratiolower is cheaper · peer median 43.4× 62.6× ✕8th of 10
- Free-cash-flow yieldhigher is cheaper · peer median 2.5% 2.3% ✕8th of 11
- Return on equityhigher is better · peer median 13% 9% –7th of 11
- Net marginhigher is better · peer median 15.0% 15.0% –6th of 11
- Revenue growthhigher is better, year on year · peer median 6.9% −0.4% ✕10th of 11
- Debt / equitylower is safer · peer median 0.54 0.09 ✓2nd of 11
- Dividend yieldamong dividend payers · peer median 0.35% 0.44% –3rd of 6
Peers are the stocks this site tracks in the same sector group, not every listed competitor. The bar runs from the weakest peer (left) to the strongest (right); the tick is the middle. Measures that don't apply to a sector (cash-flow yield for banks, debt for financials) are left out.
What would Buffett & Lynch say?
Buffett's checklist is built around durable, profitable businesses bought at sensible prices, and TECH doesn't clear enough of it yet. In its favor: TECH carries a conservative amount of debt relative to equity, converts sales into profit at healthy margins, and earns many times its interest expense, so debt service isn't a worry. Where it comes up short: TECH isn't clearing the return-on-equity bar he'd want to see right now, and its five-year average return on equity falls short too, so this isn't just a one-off dip, hasn't grown earnings per share fast enough over five years to impress him, is trading above what a conservative discounted-cash-flow estimate says it's worth right now, and trades rich relative to owner earnings, the real cash the business could pay out.
- ROE (TTM) > 11% ✕
- ROE (5yr avg) > 11% ✕
- Debt/Equity < 0.5 ✓
- Pretax margin > 15% ✓
- EPS growth (5yr) > 7% ✕
- Interest coverage > 5x ✓
- Trading below intrinsic value (DCF) ✕
- Price vs. owner earnings < 25x ✕
- Bonus: returning capital via buybacks FY2026
Lynch looked for growth stories that weren't overpriced for that growth, and TECH falls short of his bar. In its favor: TECH isn't leaning on debt to fund that growth. Where it comes up short: TECH doesn't clear the tighter PEG bar a fast grower needs to justify its pace, is growing earnings outside the 20-50% band he considered sustainable for a fast grower - either not fast enough to earn the label, or a pace he'd flag as unlikely to hold up, is priced above what he'd pay even for a company growing this quickly, and isn't generating enough free cash flow to justify a fast grower's richer price.
- PEG < 1 (stricter for fast growers) ✕
- EPS growth 20%-50% ✕
- Debt/Equity < 0.5 ✓
- P/E < 40 ✕
- Price/FCF < 40 ✕
Quantitative approximations of each investor's documented approach, not endorsed by either investor or their estates - commentary, not this site's actual ranking criteria. Buffett never published a numeric checklist: only 2 of his 8 checks here trace to his own documented concepts ("owner earnings," from his 1986 shareholder letter, and "price is what you pay, value is what you get," his case against fixed P/E/P/B ceilings) - the other 6 (ROE, debt, margins, growth, interest coverage) use commonly-cited thresholds that are not numbers he himself published. The 8 hard filters below (plus the Munger check and Graham margin of safety) are this site's real, mechanical screen and are computed completely independently of the checklists above.
Berkshire Hathaway's own filing
Which of the 8 value filters does Bio-Techne pass?
- Market Cap > $25B $11.4B
- Trailing P/E < 25 62.64
- PEG Ratio < 1.5 9.81
- Price/Book < 8 5.40
- Price/Sales < 7 9.38
- EPS Growth YoY > -5% n/a
- vs 50-day MA (±12%) Not evaluated †
- vs 200-day MA (±12%) Not evaluated †
What is Bio-Techne's margin of safety?
History tracking starts this week - check back in a future week to see how this has moved.
Where is Bio-Techne in its 52-week range?
What is the short interest in Bio-Techne?
7,385,034 shares short as of 2026-09-30 (FINRA settlement date). Reported twice a month, so this only changes roughly every two weeks, not daily.
What could go wrong with Bio-Techne? Munger's inversion check
"Invert, always invert." Instead of reasons to buy, these are reasons to hesitate, not a verdict, and not everything worth knowing about a business.
- Margin of safety, even in the bull case -50%
- Short interest under 5% of float 4.7%
- Passes most of the 6 fundamental filters 2/6 passed
- Price run-up backed by value, not just momentum +68% off 52wk low
- Debt/equity stable since 2017 0.36 → 0.10
Doesn't cover circle of competence, management quality, or accounting concerns: those need judgment, not data.
How much have Bio-Techne shareholders gained per year?
Earnings growth per share plus dividend.
An earnings-based proxy, not a stock-price total return - it doesn't capture multiple expansion/contraction or reinvested dividends. EPS from TECH's own 10-K filings; dividend yield is the current trailing yield on today's price, from the same weekly fetch as the rest of this site.
What do Bio-Techne's 10-year financials show?
From TECH's own 10-K filings (SEC EDGAR): up to the last 10 fiscal years. Press any year's bars for the exact figures.
Frequently asked questions about Bio-Techne
What kind of company is Bio-Techne?
Bio-Techne makes the reagents, proteins and instruments that researchers use in labs, and diagnostics products for hospitals. Brands and businesses it owns include R&D Systems, Novus and Lunaphore. This site groups it with Life Sciences Tools & Services stocks.
Is Bio-Techne trading above or below its DCF value?
At $72.62, TECH trades 153.4% above this site's neutral DCF value of $28.66 per share, a margin of safety of −153.4%. That DCF projects free cash flow for 10 years, with growth starting at 8% and fading to 2.5%, discounted at 10%; it is one set of assumptions, not a forecast. Test your own in the Intrinsic Value Calculator.
How many of this site's 8 value filters does Bio-Techne pass?
TECH passes 1 of 8. It passes Price/Book < 8 (5.40). It misses Market Cap > $25B ($11.4B), Trailing P/E < 25 (62.64), PEG Ratio < 1.5 (9.81) and Price/Sales < 7 (9.38). EPS Growth YoY > -5%, vs 50-day MA (±12%) and vs 200-day MA (±12%) were not evaluated, because the moving-average checks only run on stocks that clear the fundamentals first. The 8-filter list shows every stock that passes all of them.
Where is Bio-Techne trading compared with its 52-week range?
At $72.62, TECH is at its 52-week high of $72.64, 67.7% above its 52-week low of $43.30.
When does Bio-Techne report earnings next?
Bio-Techne's next earnings report is expected on November 3, 2026, with analysts expecting earnings of $0.45 per share. Dates come from the Finnhub earnings calendar and can move. In its last 4 quarters it beat the estimate 0 times, by an average of −2.6%.
Does Bio-Techne raise any of Munger's inversion flags?
TECH fails 3 of the 5 tests in this site's Munger-style inversion check, so it raises 3 flags: Margin of safety, even in the bull case (-50%); Passes most of the 6 fundamental filters (2/6 passed); and Price run-up backed by value, not just momentum (+68% off 52wk low). It passes Short interest under 5% of float and Debt/equity stable since 2017. Munger's habit was to invert the question and look for reasons to hesitate. These flags are data-driven prompts, not a verdict, and they cannot judge management, competitive position or accounting risk.
Where do these numbers come from?
- Financial statements: Bio-Techne's 10-K annual report for the year ended Jun 30, 2026, filed Aug 24, 2026 (filing index). Every earlier year in the 10-year financials comes from the company's older 10-K filings, all listed on SEC EDGAR.
- Prices and market data: quotes, P/E and analyst ratings from Finnhub; daily price history and the 52-week range from Twelve Data, both refreshed weekly. Short interest comes from FINRA, reported twice a month.
- How to check a figure: click any number in the card above to see its exact source, and read the Editorial Standards for every rule behind the checks.
About this Bio-Techne Corp analysis
This page shows every value-investing check the site runs on Bio-Techne Corp (TECH) in one place: the 8 mechanical filters, the Buffett and Lynch checklists, a margin of safety from a disclosed DCF, earnings quality, shareholder yield and how it ranks against its sector peers. The numbers come from SEC filings and public market data, refreshed weekly, and the same rules apply to every stock on the stock list. See Editorial Standards for the sources and the rules, or run your own filters in the stock screener.